Quantum Dog CPV-L

Χώρα: Ηνωμένο Βασίλειο

Γλώσσα: Αγγλικά

Πηγή: VMD (Veterinary Medicines Directorate)

Δραστική ουσία:

Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae

Διαθέσιμο από:

Intervet UK Ltd

Φαρμακολογική κατηγορία (ATC):

QI07AI05

INN (Διεθνής Όνομα):

Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae

Καθεστώς αδειοδότησης:

Expired

Αρχείο Π.Χ.Π.

Revised: April 2011
AN: 01742/2010, 02101/2010
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Quantum Dog CPV-L
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE(S): QUANTITY PER 1 ML DOSE
(MINIMUM TITRE)
Live attenuated canine Parvovirus,
strain NL-35-D low passage
10
7.0
CCID
50
*
Inactivated _Leptospira canicola_
_ _40 hamster protective doses
Inactivated _Leptospira icterohaemorrhagiae _40 hamster protective
doses.
*Cell culture infectious dose-50
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs to prevent clinical signs including
leucopenia and
reduce viral shedding caused by canine parvovirus (type 2a), and to
prevent
mortality and clinical signs including leucopenia and reduce viral
shedding caused
by canine parvovirus (types 2b and 2c) and to reduce clinical signs
and infection
due to _Leptospira canicola _and _Leptospira icterohaemorrhagiae._
Onset of immunity occurs by approximately 2 weeks after the last dose_
_of the Basic
Vaccination Scheme. Onset of immunity for the canine parvovirus
component (type
2b) occurs 7 days after a single dose when animals are vaccinated from
9 weeks of
age.
The duration of immunity is at least 12 months.
4.3
CONTRA-INDICATIONS
Do not use in unhealthy animals.
Page 1 of 4
Revised: April 2011
AN: 01742/2010, 02101/2010
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The canine parvovirus vaccinal strain may be shed from vaccinated
animals for a
number of days following vaccination. However, due to the low
pathogenicity of this
strain, it is not necessary to keep vaccinated animals separated from
non-
vaccinated animals.
High levels of maternally derived antibodies (MDA) may interfere with
the response
to vaccination. Although the vaccine has been shown to be efficacious
in the
presence levels of MDA that are likely to be encountered under field
conditions,
wher